Abstract Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) ? blockers, were immunized at least once with nonadjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNF? blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination. © 2009 Elsevier Inc. All rights reserved.

Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis Safety and immunogenicity / DEL PORTO, Flavia; Lagana', Bruno; Biselli, R.; Donatelli, I.; Campitelli, L.; Nisini, R.; Cardelli, Patrizia; Rossi, Flora; D'Amelio, Raffaele. - In: VACCINE. - ISSN 0264-410X. - 24 (16):(2006), pp. 3217-3223. [10.1016/j.vaccine.2006.01.028]

Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis Safety and immunogenicity

DEL PORTO, Flavia;LAGANA', Bruno;CARDELLI, Patrizia;ROSSI, Flora;D'AMELIO, Raffaele
2006

Abstract

Abstract Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) ? blockers, were immunized at least once with nonadjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNF? blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination. © 2009 Elsevier Inc. All rights reserved.
2006
01 Pubblicazione su rivista::01a Articolo in rivista
Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis Safety and immunogenicity / DEL PORTO, Flavia; Lagana', Bruno; Biselli, R.; Donatelli, I.; Campitelli, L.; Nisini, R.; Cardelli, Patrizia; Rossi, Flora; D'Amelio, Raffaele. - In: VACCINE. - ISSN 0264-410X. - 24 (16):(2006), pp. 3217-3223. [10.1016/j.vaccine.2006.01.028]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/236589
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 125
  • ???jsp.display-item.citation.isi??? 99
social impact